Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

D Rodman

Showing results (11-20 of 20) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 20 results.
Clinical Endocrinology|December 1, 1979
An 'artificial beta cell' for control of diabetes mellitus: effect on plasma glucagon levelsD L Horwitz, B Gonen, J B Jaspan, et al.
Chest|July 23, 1998
Cutaneous zygomycosis (mucormycosis) complicating endotracheal intubation: diagnosis and successful treatmentM Dickinson, T Kalayanamit, C A Yang, et al.
The Pharmacogenomics Journal|December 14, 2011
A pharmacogenetic study of ADRB2 polymorphisms and indacaterol response in COPD patientsR Yelensky, Y Li, S Lewitzky, et al.
Archives of Neurology|September 12, 2007
Spinchter symptoms as predictors of long-term disability in multiple sclerosisMargaret L Frazer, J Thomas Benson, Clare A Braun Hashemi, et al.
Bioorganic & Medicinal Chemistry Letters|May 6, 2003
2,4-disubstituted pyrimidines: a novel class of KDR kinase inhibitorsPeter J Manley, Adrienne E Balitza, Mark T Bilodeau, et al.
Bioorganic & Medicinal Chemistry Letters|May 6, 2004
The discovery of N-(1,3-thiazol-2-yl)pyridin-2-amines as potent inhibitors of KDR kinaseMark T Bilodeau, Leonard D Rodman, Georgia B McGaughey, et al.
Pediatric Pulmonology|July 31, 2001
Safety of aerosolized INS 365 in patients with mild to moderate cystic fibrosis: results of a phase I multi-center studyP G Noone, N Hamblett, F Accurso, et al.
Bioorganic & Medicinal Chemistry Letters|December 22, 2005
Potent 2-[(pyrimidin-4-yl)amine}-1,3-thiazole-5-carbonitrile-based inhibitors of VEGFR-2 (KDR) kinaseJohn T Sisko, Thomas J Tucker, Mark T Bilodeau, et al.
Diabetes Research and Clinical Practice|September 28, 1999
Diagnosis, screening and management of cystic fibrosis related diabetes mellitus: a consensus conference reportA Moran, D Hardin, D Rodman, et al.
Journal of Medicinal Chemistry|November 30, 2004
Potent N-(1,3-thiazol-2-yl)pyridin-2-amine vascular endothelial growth factor receptor tyrosine kinase inhibitors with excellent pharmacokinetics and low affinity for the hERG ion channelMark T Bilodeau, Adrienne E Balitza, Timothy J Koester, et al.
Pageof 2

Showing results (11-20 of 20) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 20 results.
Clinical Endocrinology|December 1, 1979
An 'artificial beta cell' for control of diabetes mellitus: effect on plasma glucagon levelsD L Horwitz, B Gonen, J B Jaspan, et al.
Chest|July 23, 1998
Cutaneous zygomycosis (mucormycosis) complicating endotracheal intubation: diagnosis and successful treatmentM Dickinson, T Kalayanamit, C A Yang, et al.
The Pharmacogenomics Journal|December 14, 2011
A pharmacogenetic study of ADRB2 polymorphisms and indacaterol response in COPD patientsR Yelensky, Y Li, S Lewitzky, et al.
Archives of Neurology|September 12, 2007
Spinchter symptoms as predictors of long-term disability in multiple sclerosisMargaret L Frazer, J Thomas Benson, Clare A Braun Hashemi, et al.
Bioorganic & Medicinal Chemistry Letters|May 6, 2003
2,4-disubstituted pyrimidines: a novel class of KDR kinase inhibitorsPeter J Manley, Adrienne E Balitza, Mark T Bilodeau, et al.
Bioorganic & Medicinal Chemistry Letters|May 6, 2004
The discovery of N-(1,3-thiazol-2-yl)pyridin-2-amines as potent inhibitors of KDR kinaseMark T Bilodeau, Leonard D Rodman, Georgia B McGaughey, et al.
Pediatric Pulmonology|July 31, 2001
Safety of aerosolized INS 365 in patients with mild to moderate cystic fibrosis: results of a phase I multi-center studyP G Noone, N Hamblett, F Accurso, et al.
Bioorganic & Medicinal Chemistry Letters|December 22, 2005
Potent 2-[(pyrimidin-4-yl)amine}-1,3-thiazole-5-carbonitrile-based inhibitors of VEGFR-2 (KDR) kinaseJohn T Sisko, Thomas J Tucker, Mark T Bilodeau, et al.
Diabetes Research and Clinical Practice|September 28, 1999
Diagnosis, screening and management of cystic fibrosis related diabetes mellitus: a consensus conference reportA Moran, D Hardin, D Rodman, et al.
Journal of Medicinal Chemistry|November 30, 2004
Potent N-(1,3-thiazol-2-yl)pyridin-2-amine vascular endothelial growth factor receptor tyrosine kinase inhibitors with excellent pharmacokinetics and low affinity for the hERG ion channelMark T Bilodeau, Adrienne E Balitza, Timothy J Koester, et al.
Pageof 2